TEVA PHARMACEUTICALS USA, INC.

Lobbying for TEVA PHARMACEUTICALS USA INC

Filing 4th Quarter - Report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 14, 2026

Expenses

$360,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

New Jersey

Official filing document

Government bodies contacted 9

Centers For Medicare and Medicaid Services (CMS)
Commerce, Dept of (DOC)
Executive Office of the President (EOP)
Food & Drug Administration (FDA)
Health & Human Services, Dept of (HHS)
Homeland Security, Dept of (DHS)
HOUSE OF REPRESENTATIVES
SENATE
U.S. Trade Representative (USTR)

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 3

SJRES 37
A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada.
S 959
Tariff Transparency Act of 2025
HR 6888
Trump Tariff Transparency Act

Lobbying activity 2

Health Issues

Use of Section viii statements in pharmaceutical labeling. Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and legislation to reform pharmacy benefit managers. Patent reform legislation. Proposals related to drug shortages. Reauthorization of the Pandemic and All Hazards Preparedness Act (PAHPA). Proposals related to biosimilar drugs.

Tariff (miscellaneous tariff bills)

A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada (S.J.Res.37). Tariff Transparency Act of 2025 (S.959) and Trump Tariff Transparency Act (H.R.6888).

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.